CytomX halts lead program and will seek a partner as breast cancer drug disappoints - Endpoints News

Mixed Phase II results are forcing CytomX to slam the brakes on one of its lead cancer drugs — unless it can convince a partner to help take it further. The data come from a study of praluzatamab ravtansine, CytomX’s take on a CD166-targeting antibody-drug co…

Mixed Phase II re­sults are forc­ing Cy­tomX to slam the brakes on one of its lead can­cer drugs — un­less it can con­vince a part­ner to help take it fur­ther. The da­ta come from a study of praluz… [+3769 chars]

full article...